logo-loader
HealthPharma & Biotech
Bard1 Life Sciences Ltd

BARD1 Life Sciences Ltd raising funds for novel cancer diagnostics

The company is developing diagnostic tests for early detection of cancer.

CancerHeadline.jpg
The technology is based on BARD1, a potent tumour suppressor

BARD1 Life Sciences Ltd (ASX:BD1) has received binding commitments to raise $1,097,325 via the issue of shares to sophisticated and professional investors at an issue price of $0.008 per share.

The company will also conduct a share purchase plan (SPP) for eligible shareholders to raise up to a further $1 million at the same issue price.

Funds raised from the placement and SPP will be used to fund ongoing research and development programs, commercial initiatives and for general working capital purposes.

BARD1 is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer.

The company’s proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and an important tumour biomarker in cancer.

BARD1’s lead product, the BARD1 Lung Cancer Test, is a non-invasive blood test in development for early detection of lung cancer.

The company is also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers.

BARD1’s research activities are currently performed under a research contract at the University of Geneva (UNIGE).

The company’s business strategy is to focus on leveraging its BARD1 Technology to develop diagnostic tests for early detection of cancer where there are clear unmet needs and product advantages.

Quick facts: Bard1 Life Sciences Ltd

Price: $0.03

Market: ASX
Market Cap: $41.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'May only be a matter of time' before Uranium price recovery with...

Mining Capital's Alastair Ford discusses the planned slow down in production from Kazatomprom (LON:KAP). The miner's looking to cut output from its Kazakh mines by around 20% through to 2021. He says that extends the timeframe of its previous production curtailment by a further year, and...

2 days, 10 hours ago

2 min read